Evidence map›Paper›PMID 37325043›Full record

ArticleFrontiers in neuroscience2023

Vertigoheel promotes rodent cognitive performance in multiple memory tests.

Kerstin Ott, Taneli Heikkinen, Kimmo K Lehtimäki, Kaisa Paldanius, Jukka Puoliväli, Raimo Pussinen, Emile Andriambeloson, Bertrand Huyard, Stéphanie Wagner, Cathrin Schnack and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Kerstin OttHeel GmbH, Baden-Baden, Germany.
Taneli HeikkinenCharles River Discovery Services, Kuopio, Finland.
Kimmo K LehtimäkiCharles River Discovery Services, Kuopio, Finland.
Kaisa PaldaniusCharles River Discovery Services, Kuopio, Finland.
Jukka PuoliväliCharles River Discovery Services, Kuopio, Finland.
Raimo PussinenCharles River Discovery Services, Kuopio, Finland.
Emile AndriambelosonNeurofit SAS, Illkirch, France.
Bertrand HuyardNeurofit SAS, Illkirch, France.
Stéphanie WagnerNeurofit SAS, Illkirch, France.
Cathrin SchnackDepartment of Neurology, Ulm University, Ulm, Germany.
Anke WahlerDepartment of Neurology, Ulm University, Ulm, Germany.
Bjoern von EinemDepartment of Neurology, Ulm University, Ulm, Germany.
Christine A F von ArnimDepartment of Neurology, Ulm University, Ulm, Germany.
Yvonne BurmeisterHeel GmbH, Baden-Baden, Germany.
Kathrin WeyerHeel GmbH, Baden-Baden, Germany.
Bernd SeilheimerHeel GmbH, Baden-Baden, Germany.
Heel (Germany) · DEUniversität Ulm · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cognitive impairment associated with old age or various brain disorders may be very disabling for affected individuals, placing their carers and public health services under considerable stress. The standard-of-care drugs produce only transient improvement of cognitive impairment in older people, so the search for novel, safe and effective therapeutics that would help to reverse or delay cognitive impairment is warranted. Repurposing pharmacological therapies with well-established safety record for additional indications is a promising recent trend in drug development. Vertigoheel (VH-04), a multicomponent drug made of Methods: In the majority of behavioral experiments, namely in the spontaneous and rewarded alternation tests, passive avoidance test, contextual/cued fear conditioning, and social transmission of food preference, we examined the ability of single and repeated intraperitoneal administrations of VH-04 to improve cognitive parameters of mice and rats disrupted by the application of the muscarinic antagonist scopolamine. In addition, we also assessed how VH-04 affected novel object recognition and influenced performance of aged animals in Morris water maze. Furthermore, we also studied the effects of VH-04 on primary hippocampal neurons Results: Administration of VH-04 positively influenced visual recognition memory in the novel object recognition test and alleviated the impairments in spatial working memory and olfactory memory caused by the muscarinic antagonist scopolamine in the spontaneous alternation and social transmission of food preference tests. In addition, VH-04 improved retention of the spatial orientation memory of old rats in the Morris water maze. In contrast, VH-04 did not have significant effects on scopolamine-induced impairments in tests of fear-aggravated memory or rewarded alternation. Experiments Discussion: Our findings allow a cautious conclusion that in addition to its ability to alleviate manifestations of vertigo, VH-04 may be also used as a cognitive enhancer.

Indexed as

forgetfulnessmulticomponent drugneurite lengtholfactory memoryspatial orientation memoryspatial working memoryVertigoheelvisual recognition memory

Identifiers

PMID37325043
PMCPMC10264630
OpenAlexW4378902413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.